Released Nov 5, 2021, before the open
10-Q filed Nov 5, 2021, 36 days after period end · 0001564590-21-054754
Q3 2021 · 10-Q
Revenue$112.43M$112.43M +1.3% vs Q3 2020−7.4% vs Q2 2021
Net Income-$2.17M-$2.17M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted$0.11$0.11 −54.2% vs Q3 2020−8.3% vs Q2 2021
Gross Profit$84,121,000−0.7%
Operating Income-$313,000N/M
Operating Cash Flowderived$6,432,000−70.6%
Free Cash Flowderived$3,907,000−79.2%
Margins · derived
Gross margin74.8%−1.5 pt vs Q3 2020
Operating margin-0.3%−4.0 pt vs Q3 2020
Net margin-1.9%−6.1 pt vs Q3 2020
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $112.43M | $110.99M | $113.50M | $111.71M |
| Net Income | -$2.17M | $4.65M | -$40.50M | -$1.21M |
| EPS Diluted | $0.11 | $0.24 | -$2.14 | -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR